About Dr. Santana-Davila
Dr. Rafael Santana-Davila leads the medical oncology department at the Swedish Cancer Institute First Hill. His expertise focuses on asbestos-related diseases and thoracic oncology, including mesothelioma and lung cancers. He believes compassionate, evidence-based care empowers patients facing complex diagnoses.
“It is our responsibility to offer the best possible treatment, providing state-of-the-art care within a multidisciplinary team,” he tells us. “My goal is to provide patients and their families the most up-to-date and clear information about their disease, prognosis and treatment options.”
Medical Education & Expertise
- Swedish Cancer Institute First Hill
- University of Washington (Associate Professor)
- Seattle Cancer Care Alliance
- Fred Hutchinson Cancer Center (Associate Professor)
- Medical College of Wisconsin
- Mayo Clinic (Fellowship)
- University of Minnesota (Residency)
- Universidad Anahuac Escuela de Medicina (M.D.)
Associations, Awards & Recognition
- Best Teacher Award, Graduating Class of Medical Student University of Minnesota, 2006
- Board-certified in Medical Oncology, American Board of Internal Medicine
- CMS Meaningful Use Stage 1 Certification
- Small Grant Program Award, Mayo Clinic Department of Oncology, 2009
Why Choose Dr. Santana-Davila for Mesothelioma?
Dr. Santana-Davila specializes in understanding how mesothelioma cells spread, grow and die at the genetic level. His research helps predict which patients will respond best to specific treatments, allowing for more personalized care plans. At his cancer center, he uses advanced technology including Gamma Knife radiation systems and an on-site laboratory for fast, accurate diagnostics. Patients benefit from his approach of applying the latest research findings directly to their individual treatment.
“We have come a long way [in treating cancer] from a few decades ago, but there still is a lot of work to do,” he says. “I want to continue seeking advances in therapeutic options for patients with cancer.”
He adds, “My interest in oncology grew from two things: First from a fascination with trying to understand the process of why cancer develops. And secondly, and probably most importantly, is because while caring for cancer patients, they invariably teach you a variety of life lessons that make you a better person.”
Publications of Dr. Santana-Davila
- Santana-Davila, R., et al. (2024, October 8). A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial). Retrieved from https://ascopubs.org/doi/10.1200/JCO.24.00533
- Santana-Davila, R. (2022, June). Chemo and Immuno-Therapeutic Options for Nonsmall Cell Lung Cancer Lung Cancer. Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S0039610922000135?via%3Dihub
- Santana-Davila, R., et al. (2018, October). NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. Retrieved from https://jnccn.org/view/journals/jnccn/16/10/article-p1171.xml
- Santana-Davila, R., et al. (2014, November 24). Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiotherapy for Stage III Non–Small-Cell Lung Cancer: An Analysis of Veterans Health Administration Data. Retrieved from https://ascopubs.org/doi/10.1200/JCO.2014.56.2587
- Santana-Davila, R., et al. (2012, October). Evaluation and Management of Elderly Patients With Lung Cancer. Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S1053429612000501?via%3Dihub